

Original Article  
Public Health &  
Preventive Medicine



# Safety of COVID-19 Vaccination During Pregnancy and Lactation: A VigiBase Analysis

Dayeon Kang ,<sup>1\*</sup> Ahhyung Choi ,<sup>2\*</sup> Suneun Park ,<sup>2</sup> Seung-Ah Choe ,<sup>3</sup> and Ju-Young Shin <sup>1,2,4</sup>

<sup>1</sup>Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea

<sup>2</sup>School of Pharmacy, Sungkyunkwan University, Suwon, Korea

<sup>3</sup>Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea

<sup>4</sup>Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Korea



Received: Jul 10, 2023

Accepted: Oct 16, 2023

Published online: Nov 29, 2023

Address for Correspondence:

Ju-Young Shin, PhD

School of Pharmacy, Sungkyunkwan University,  
2066 Seobu-ro, Jangan-gu, Suwon 16419,  
Republic of Korea.  
Email: shin.jy@skku.edu

\*Dayeon Kang and Ahhyung Choi contributed  
equally as co-first authors.

© 2024 The Korean Academy of Medical  
Sciences.

This is an Open Access article distributed  
under the terms of the Creative Commons  
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)  
which permits unrestricted non-commercial  
use, distribution, and reproduction in any  
medium, provided the original work is properly  
cited.

ORCID iDs

Dayeon Kang   
<https://orcid.org/0009-0007-5731-6734>  
Ahhyung Choi   
<https://orcid.org/0000-0002-0101-7328>  
Suneun Park   
<https://orcid.org/0009-0000-4703-322X>  
Seung-Ah Choe   
<https://orcid.org/0000-0001-6270-5020>  
Ju-Young Shin   
<https://orcid.org/0000-0003-1010-7525>

Funding

This research was supported by a grant  
(22183MFDS433) from the Ministry of Food

## ABSTRACT

**Background:** There is limited evidence on the safety of coronavirus disease 2019 (COVID-19) vaccination during pregnancy and lactation. Thus, we aimed to evaluate the association between COVID-19 vaccination during pregnancy and lactation and reporting risk of adverse pregnancy or lactation outcomes.

**Methods:** Using VigiBase, we performed a disproportionality analysis with case/non case design. Cases were defined based on the Standardized MedDRA Queries (SMQs) of “pregnancy and neonatal topics” and non-cases were defined as all other adverse events. We included all reports with COVID-19 vaccines as the suspected cause. Using the full database as the comparators, reporting odds ratios (RORs) with 95% confidence intervals (CIs) were estimated by logistic regression while adjusting for maternal age. Infants’ age and sex were additionally adjusted in analyzing the risk of COVID-19 vaccination during lactation.

**Results:** We identified 10,266 and 6,474 reports with the SMQ of “pregnancy and neonatal topics” associated with COVID-19 vaccines during pregnancy and lactation, respectively. No significant RORs of adverse pregnancy outcomes associated with COVID-19 vaccines during pregnancy were observed; however, “functional lactation disorders” showed significant disproportionality during lactation with adjusted ROR of 1.48 (95% CI, 1.21–1.79). Further analysis that analyzed “functional lactation disorders” at a preferred term level, showed higher ROR in mastitis (2.76 [95% CI, 1.45–5.27]).

**Conclusion:** Overall, we did not observe a positive association between COVID-19 vaccination during pregnancy and risk of reporting adverse pregnancy outcomes. However, we found a significant disproportionate reporting association between COVID-19 vaccination during lactation and “functional lactation disorders”, specifically mastitis. Continuous surveillance is warranted to confirm the safety of COVID-19 vaccine during pregnancy and lactation.

**Keywords:** COVID-19 Vaccine; Pregnancy; Adverse Pregnancy Outcomes; VigiBase

## INTRODUCTION

Few years into the coronavirus disease 2019 (COVID-19) pandemic, the COVID-19 vaccines have been widely used to prevent the rapid spread of the disease and severe complications

and Drug Safety, South Korea, in 2022-2025 and by a grant (22153MFDS607) from the Ministry of Food and Drug Safety, South Korea in 2021-2025.

#### Disclosure

Dr. Shin received grants from the Ministry of Food and Drug Safety, the National Research Foundation of Korea, and pharmaceutical companies, including Pfizer, Celltrion, and SK Bioscience. No other relationships or activities have influenced the submitted work.

#### Author Contributions

Conceptualization: Kang D, Choi A, Shin JY.  
Data curation: Kang D, Choi A. Formal analysis: Kang D. Methodology: Kang D, Choi A. Writing - original draft: Kang D, Choi A. Writing - review & editing: Kang D, Choi A, Park S, Choe SA, Shin JY.

after the infection.<sup>1,2</sup> Pregnant populations were also recommended to receive COVID-19 vaccination given that pregnancy is an independent risk factor for severe COVID-19.<sup>3-5</sup> Moreover, previous studies have shown that pregnant women with COVID-19 have higher risk of severe complications (i.e., intensive care unit admission and death) and the adverse perinatal outcomes (e.g., preterm birth),<sup>4,6-10</sup> although the vertical transmission appeared to occur in minority cases.<sup>11,12</sup> Accordingly, the US Centers for Disease Control and Prevention recommended COVID-19 vaccination to pregnant populations on 11 August 2021, and Korea Disease Control and Prevention Agency also announced the recommendation in October 2021.<sup>3,13</sup> Similarly, breastfeeding women are recommended to receive COVID-19 vaccination as there are potential benefits including the production of antibodies that can be passed on to the infant through breast milk.<sup>14</sup> However, because pregnant and lactating women were largely excluded from the pre-authorization clinical trials of COVID-19 vaccines, potential risk after the COVID-19 vaccination in these populations were of concern.

To date, available evidence on the safety of COVID-19 vaccination during pregnancy and lactation are limited. In preliminary findings, there were no increased risk of adverse events associated with COVID-19 vaccination during pregnancy.<sup>15</sup> Following epidemiological studies also showed no significantly increased risk in pregnancy-related outcomes, including spontaneous abortions,<sup>16,17</sup> miscarriage,<sup>18</sup> and preterm birth.<sup>19,20</sup> However, there is a need to further evaluate the safety of COVID-19 vaccination during pregnancy, as previous studies mainly focused on specific outcomes rather than investigating the overall adverse pregnancy outcomes that can occur during pregnancy or after birth in infants. Likewise, while studies have reported general adverse events after COVID-19 vaccination in lactating women such as swelling and injection site pain,<sup>21</sup> additional study is needed to better understand potential lactation-related adverse events or any impact on neonatal health after COVID-19 vaccination.

Pharmacovigilance database contains information on adverse drug reactions (ADRs) in real-world setting and have been widely used to detect potential signals associated with drugs.<sup>22</sup> Using the global individual case safety reports (ICSRs) database, Vigibase, we aimed to explore the potential associations between the COVID-19 vaccination during pregnancy and lactation and adverse pregnancy-related outcomes.

## METHODS

### Data source

We performed a pharmacovigilance study using Vigibase, the World Health Organization (WHO)'s global database of ICSRs managed by the Uppsala Monitoring Centre. It contains more than 30 million safety reports of suspected ADRs, submitted by over 150 countries. The database includes information on patient's demographics, suspected drugs, suspected ADRs coded with Medical Dictionary for Regulatory Activities (MedDRA) terminology, reporter type, and country of origins.<sup>23</sup> As the database contains de-identified data, patients' informed consent was not required.

### Data retrieval

Among all deduplicated reports identified from inception to 31 December 2022, we first included all case reports reporting Standardized MedDRA queries (SMQs) of "Pregnancy and neonatal topics", with COVID-19 vaccines as suspected drug. Among the identified reports, those in women aged 12 to 44 years were selected. When analyzing the safety signals for

COVID-19 vaccination during lactation, reports with infants aged below 23 months were additionally included. To retrieve reports associated with COVID-19 vaccination during pregnancy, we used the following preferred terms (PTs) which belong to the SMQs of “Pregnancy and neonatal topics”: “Exposure during pregnancy”, “Foetal exposure during pregnancy” and “Maternal exposure during pregnancy”. Case reports without these PT were excluded to minimize the possibility of including the ADRs not associated with COVID-19 vaccination during pregnancy. In addition, reports with the PT of “Exposure via breast milk” and “Maternal exposure during breastfeeding” were considered as adverse events associated with COVID-19 vaccination during lactation.

### Case/non-case design

In this study, we implemented case/non-case design to assess safety signals associated with COVID-19 vaccination during pregnancy and lactation. We identified the cases using the SMQs of “Pregnancy and neonatal topics”, which are validated standard sets of MedDRA terms. The SMQs of “Pregnancy and neonatal topics” are sub-organized by several SMQs: “Congenital, familial and genetic disorders,” “Foetal disorders,” “Neonatal disorders,” “Pregnancy, labour and delivery complications and risk factors (excl. abortions and stillbirth),” “Termination of pregnancy and risk of abortion,” “Lactation- related topics,” and “Normal pregnancy conditions and outcomes.”<sup>24</sup>

Cases for pregnancy analysis were defined as “Congenital, familial and genetic disorders,” “Neonatal disorders,” “Termination of pregnancy and risk of abortion,” “Pregnancy, labour and delivery complications and risk factors (excl. abortion and stillbirth),” and “Foetal disorders.” For lactation analysis, “Neonatal disorders” and “Functional lactation disorders” were defined as cases. Non-cases were all other reports in the Vigibase.

### Statistical analysis

Disproportionality analysis was conducted to evaluate whether adverse events were differentially reported for the COVID-19 vaccine during pregnancy and lactation compared to the full database. Reporting odds ratios (RORs) with 95% confidence intervals (CIs) of adverse outcomes were estimated using logistic regression models, while adjusting for maternal age. We also adjusted for infant age and infant sex when assessing the reporting risk associated with COVID-19 vaccination during lactation. To be identified as a signal, the lower limit of the ROR's 95% CI had to be higher than 1.00, and also the number of cases should be more than 5 to reduce false positives.<sup>25</sup> All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

### Sensitivity analyses

In sensitivity analyses, we assessed safety signals of COVID-19 vaccines by using the influenza vaccines as comparator group, instead of all other drugs in the database. Although we used full database as comparators in our main analysis to reduce the false positivity,<sup>26</sup> evaluating the safety profile of COVID-19 vaccines as compared with other vaccines may provide further relevant evidence. Because previous studies have shown that influenza vaccination during pregnancy or lactation were not associated with adverse outcomes, influenza vaccines were selected as the comparator group.<sup>27-30</sup> Additionally, we restricted the ICSRs notified by physicians to examine the robustness of our main findings.

Lastly, as a post-hoc analysis, we further analyzed the “functional lactation disorders” at a PT level, which was identified as a potential signal associated with COVID-19 vaccination during lactation.

### Ethics statement

This study was approved by the Institutional Review Board (IRB) of Sungkyunkwan University and the requirement for informed consent was waived (IRB No. 2023-02-038).

## RESULTS

### Characteristics of reports


From inception through 31 December 2022, there were 33,188,305 ICSRs reported in the database. After applying the exclusion criteria, 16,740 reports reporting SMQs of “Pregnancy and neonatal topics” with COVID-19 vaccines as suspected drug remained; 10,266 reports associated with COVID-19 vaccine during pregnancy and 6,474 reports associated with COVID-19 vaccine during lactation (**Fig. 1**). As COVID-19 vaccines were first commercialized on December 11, 2020,<sup>1</sup> all the reports associated with COVID-19 vaccines were reported from 2021.

Overall, most of the safety reports associated with exposure during pregnancy were reported from women aged 18 to 44 years ( $n = 10,215$  [99.50%]) and were from the Region of the Americas ( $n = 5,616$  [54.70%]) and Europe ( $n = 4,309$  [41.97%]) (**Table 1**). Except for the reports without notifiers, the reports were mostly notified by consumer or other non-health professionals.

Likewise, majority of the safety reports associated with COVID-19 vaccines during lactation were reported from women aged 18 to 44 years ( $n = 5,944$  [91.81%]). Of 565 reports reported from the infants, 281 (53.52%) were from male infants. The reports were mainly originated from Europe ( $n = 5,538$  [85.54%]) and were notified by consumer or other non-health professionals ( $n = 5,003$  [77.27%]).

### Adverse events associated with COVID-19 vaccine during pregnancy

There were no significant disproportional associations between the COVID-19 vaccines during pregnancy and the SMQs of “Pregnancy and neonatal topics”; the adjusted ROR (aROR) was 0.29 (95% CI, 0.23–0.37) for congenital, familial and genetic disorders, 0.81 (0.75–0.87) for foetal disorders, 0.24 (0.19–0.31) for neonatal disorders, 0.34 (0.33–0.36)



**Fig. 1.** Flowchart of reports with COVID-19 vaccines during pregnancy and lactation.

SMQ = Standardized Medical Dictionary for Regulatory Activities Query, COVID-19 = coronavirus disease 2019.

**Table 1.** Baseline characteristics of “Pregnancy and neonatal topics” reports with COVID-19 vaccines

Variables	Exposure during pregnancy (n = 10,266)	Exposure during lactation (n = 6,474)
Age group		
Women		
12–17	51 (0.50)	5 (0.08)
18–44	10,215 (99.50)	5,944 (91.81)
Infant		
0–27 days	N/A	15 (0.23)
28 days to 23 mon	N/A	510 (7.88)
Infant's sex <sup>a</sup>		
Male	N/A	281 (53.52)
Female	N/A	244 (46.48)
Region		
European	4,309 (41.97)	5,538 (85.54)
Region of the Americas	5,616 (54.70)	776 (11.99)
Western Pacific	240 (2.34)	42 (0.65)
Eastern Mediterranean	11 (0.11)	2 (0.03)
South-East Asia	5 (0.05)	17 (0.26)
African	85 (0.83)	99 (1.53)
Notifier		
Physician	379 (3.69)	153 (2.34)
Pharmacist	92 (0.89)	197 (3.04)
Other health professional	428 (4.16)	340 (5.25)
Lawyer	3 (0.03)	2 (0.03)
Consumer or other non-health professional	3,822 (37.22)	5,003 (77.27)
Unknown	5,542 (53.98)	779 (12.03)
Report type		
Spontaneous	8,778 (85.51)	6,190 (95.61)
Report from study	1,488 (14.49)	284 (4.39)
Reporting year		
2021	7,964 (77.58)	5,241 (80.95)
2022	2,300 (22.40)	1,232 (19.03)
Unknown	2 (0.02)	1 (0.02)
Seriousness		
Yes	3,886 (37.79)	2,480 (38.31)
No	6,380 (62.21)	3,994 (61.69)

Values are presented as number (%).

COVID-19 = coronavirus disease 2019, N/A = not available.

<sup>a</sup>Infants' sex was only reported from 525 reports originating from infants.


for pregnancy, labour, and delivery complications and risk factors, and 0.88 (0.84–0.92) for termination of pregnancy and risk of abortion (**Fig. 2**).

### Adverse events associated with COVID-19 vaccine during lactation

However, as described in **Fig. 2**, the “Functional lactation disorders” showed a significant disproportionate reporting for COVID-19 vaccines during lactation (aROR, 1.48 [95% CI, 1.21–1.79]), whereas the SMQ of “neonatal disorders” did not show significant aROR (0.35 [0.27–0.45]).


### Functional lactation disorders associated with COVID-19 vaccines

Additional analysis was conducted for the SMQ of “Functional lactation disorders” at a PT level, associated with COVID-19 vaccine during lactation. We identified a significant disproportionality signal for mastitis associated with COVID-19 vaccine during lactation, with aROR (95% CI) of 2.76 (1.45–5.27) (**Fig. 3**). Other PTs showed no significant reporting risk.



**Fig. 2.** Disproportionality analysis on the SMQs of “Pregnancy and neonatal topics” associated with COVID-19 vaccines during pregnancy and lactation. SMQ = Standardized Medical Dictionary for Regulatory Activities Query, N<sub>COVID</sub> = number of reports with COVID-19 vaccine as suspected drug, ROR = reporting odds ratio, CI = confidence interval, COVID-19 = coronavirus disease 2019.

<sup>a</sup>For pregnancy analysis, maternal age was adjusted and for lactation analysis, maternal age, infant age, and infant sex were adjusted.



**Fig. 3.** Disproportionality analysis for reporting “Functional lactation disorders” associated with COVID-19 vaccines during lactation at a PT level. PT = preferred term, N<sub>COVID</sub> = number of reports with COVID-19 vaccine as suspected drug, aROR = adjusted reporting odds ratio, CI = confidence interval, COVID-19 = coronavirus disease 2019.

## Sensitivity analyses

Sensitivity analyses generally showed consistent results with our main analyses (Table 2). When compared with influenza vaccines, there were no disproportional signals associated with COVID-19 vaccines during pregnancy and lactation. Also, similar results were observed in analyses restricting the reports notified by physicians, except for small increased reporting risk observed for “termination of pregnancy and risk of abortion” associated with COVID-19 vaccination during pregnancy.

## DISCUSSION

Previous study has reported that the most common reason for COVID-19 vaccination hesitancy in pregnant women was concern that COVID-19 vaccine might affect the fetus.<sup>31</sup> In light of this and the limited available evidence on the safety of COVID-19 vaccine, our study used the global WHO database of ADRs and investigated the potential signals associated with COVID-19 vaccination during pregnancy or lactation. We utilized the SMQs of “pregnancy and neonatal topics”, which are predefined sets of MedDRA terms that are associated with the pregnancy or neonatal-related conditions, to detect any potential signals. Overall, we did not identify



**Table 2.** Sensitivity analyses on the risk of reporting SMQs of “Pregnancy and neonatal topics”

Sensitivity analysis	N <sub>COVID</sub>	aROR (95% CI)
Compared with influenza vaccines		
During pregnancy		
Congenital, familial and genetic disorders	74	1.03 (0.56–1.90)
Foetal disorders	750	0.55 (0.47–0.63)
Neonatal disorders	75	0.50 (0.32–0.79)
Pregnancy, labour and delivery complications and risk factors	1,920	0.61 (0.55–0.67)
Termination of pregnancy and risk of abortion	2,406	0.83 (0.75–0.92)
During lactation		
Functional lactation disorders	578	0.70 (0.26–1.91)
Neonatal disorders	94	1.30 (0.29–5.89)
Reports notified by physicians		
During pregnancy		
Congenital, familial and genetic disorders	4	0.24 (0.06–0.97)
Foetal disorders	15	0.60 (0.36–1.00)
Neonatal disorders	3	0.19 (0.05–0.76)
Pregnancy, labour and delivery complications and risk factors	67	0.48 (0.37–0.61)
Termination of pregnancy and risk of abortion	124	2.16 (1.78–2.63)
During lactation		
Functional lactation disorders	10	1.82 (0.74–4.50)
Neonatal disorders	5	0.38 (0.13–1.09)

SMQs = Standardized Medical Dictionary for Regulatory Activities Queries, N<sub>COVID</sub> = number of reports with COVID-19 vaccine as suspected drug, aROR = adjusted reporting odds ratio, CI = confidence interval.

any disproportional signal on pregnancy-related adverse events associated with the COVID-19 vaccine during pregnancy; however, there was significant disproportionate reporting of “functional lactation disorders” associated with the COVID-19 vaccine during lactation, with an aROR (95% CI) of 1.48 (1.21–1.79). Further analysis that analyzed “functional lactation disorders” at a PT level, showed higher ROR in mastitis (2.76 [95% CI, 1.45–5.27]).

Our findings are supported by the previous epidemiologic studies and review articles which found no association between COVID-19 vaccination during pregnancy and adverse pregnancy-related outcomes.<sup>5,32–35</sup> Because pregnant women are typically excluded from the randomized clinical trials owing to ethical restrictions, information on the vaccines safety during pregnancy mostly relies on the observational studies.<sup>32</sup> Earlier meta-analysis on the perinatal outcomes of COVID-19 vaccination in pregnancy found no evidence of a higher risk of adverse outcomes (e.g., miscarriage, postpartum haemorrhage, low birth weight) associated with COVID-19 mRNA vaccination in pregnancy.<sup>33</sup> Similar results were found by subsequent cohort study using the pregnancy registry of Sweden and Norway.<sup>34</sup> This study observed no significantly increased risk of adverse pregnancy outcomes including preterm birth, stillbirth, and low Apgar score among individuals vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy compared with those without SARS-CoV-2 vaccination during pregnancy. Another population-based cohort study in Canada reported that COVID-19 vaccination during pregnancy, primarily mRNA vaccines administered in the second and third trimester, was not associated with an increased risk of adverse peripartum outcomes.<sup>35</sup> In our study, we performed a disproportionality analysis using the largest pharmacovigilance database and did not find any significant signals associated with COVID-19 vaccination during pregnancy. According to the KCDC reports, the most common adverse events reported from the pregnant women was headache (n = 10) followed by stomachache (n = 10) and muscleache (n = 8), which is relatively mild.<sup>36</sup> Considering these results together in alignment with the current recommendation, COVID-19 vaccination during pregnancy should be considered when the expected benefits are considered to outweigh the potential risks.<sup>37–40</sup>

However, we found an increased reporting risk of “functional lactation disorder”, specifically mastitis, associated with COVID-19 vaccination in lactating women. To date, limited number of studies have investigated the safety of COVID-19 vaccination during lactation. An online prospective cohort study in U.S reported that COVID-19 vaccines were well-tolerated among the lactating women.<sup>41</sup> Another study based on self-reported online questionnaire found no severe adverse events for mothers or infants after COVID-19 vaccination during lactation.<sup>42</sup> In the previous studies, the most frequently reported adverse events after COVID-19 vaccination during lactation were injection site pain, fatigue, and headache, which are relatively mild and similar to those observed in the general population. On the other hand, lactation related adverse events such as mastitis and suppressed lactations were not commonly reported. One study of lactating healthcare workers in Singapore reported that three of 88 (3.4%) participants had mastitis after two doses of BNT162b2 (Pfizer/BioNTech) vaccination,<sup>43</sup> whereas in another cross-sectional survey, 0.2% of breastfeeding mothers reported a mastitis after COVID-19 vaccination.<sup>42</sup> Given that the incidence of mastitis in the general breastfeeding population ranges from 2.5% to 20%, further studies should be conducted to confirm whether COVID-19 vaccination during lactation is associated with mastitis. Meanwhile, according to one case report of post COVID-19 vaccine mastitis, the type of mastitis was self-limited and the symptom spontaneously disappeared in 6 days.<sup>44</sup> Therefore, while awaiting for additional studies to confirm the safety of COVID-19 vaccination during lactation, COVID-19 vaccine should be considered in lactating women based on the recommendation of the CDC and WHO.<sup>45,46</sup>

To the best of our knowledge, this is the first study using the world’s largest pharmacovigilance database to examine the pregnancy and lactation related adverse events in association with COVID-19 vaccination as providing a quantitative measure of the ROR in comparison to all other drugs. Although several well-conducted epidemiological studies<sup>16,17,20,35</sup> have addressed the safety of COVID-19 vaccination during pregnancy, limited evidence exists regarding the safety of COVID-19 vaccination during lactation.<sup>47,48</sup> Moreover, disproportionality analysis, a validated method used in drug safety studies, would still be informative to detect any potential signals associated with COVID-19 vaccination during pregnancy that may not have been the outcomes of interest in previous cohort studies.

This study has several limitations which are mostly inherent to studies using a pharmacovigilance database. First, given the spontaneous nature of ADR reporting in VigiBase, underreporting is unavoidable. However, the effect of underreporting would be low to change the results of the disproportionality analysis.<sup>49</sup> Second, information on some variables may be incomplete. In our analysis, we excluded the reports with missing data on the basic demographics such as age and sex. Third, information on the detailed timing of exposure during pregnancy (e.g., trimester) and the dose of vaccines were unavailable in the VigiBase. Future studies are needed to assess the safety according to the timing of exposure and the dose effect. Lastly, although we used the global pharmacovigilance database, majority of the reports were originated from Europe and the region of America; thus, the results may not be generalizable to other regions. This may be due to the different policies across the countries regarding the COVID-19 vaccination during pregnancy or lactation. Therefore, additional analysis including the reports from other countries and regions would be beneficial.

This large pharmacovigilance study suggests that COVID-19 vaccination during lactation increased the risk of reporting functional lactation disorders, specifically mastitis, whereas



no significant risk of reporting adverse pregnancy outcomes was observed after COVID-19 vaccination during pregnancy. However, considering that COVID-19 vaccine is a newly developed vaccine, continuous surveillance is warranted, especially on the long-term safety, to confirm the safety of COVID-19 vaccine during pregnancy and lactation.

## REFERENCES

1. FDA. Pfizer-BioNTech COVID-19 vaccines. <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines#additional>. Updated 2023. Accessed March 28, 2023.
2. CDC. COVID-19 vaccine Emergency Use Authorization (EUA) fact sheets for recipients and caregivers. <https://www.cdc.gov/vaccines/covid-19/eua/index.html>. Updated 2021. Accessed March 28, 2023.
3. Park WB, Hwang YH, Cheong HJ. COVID-19 vaccination in Korea. *Infect Chemother* 2023;55(1):135-49.  
[PUBMED](#) | [CROSSREF](#)
4. Hong SH, Shi HJ, Kim SY, Park Y, Eom JS. Clinical characteristics and pregnancy-related outcomes of pregnant women hospitalized with COVID-19 during the delta wave: a single-center observational study. *Infect Chemother* 2022;54(3):433-45.  
[PUBMED](#) | [CROSSREF](#)
5. Badell ML, Dude CM, Rasmussen SA, Jamieson DJ. COVID-19 vaccination in pregnancy. *BMJ* 2022;378:e069741.  
[PUBMED](#) | [CROSSREF](#)
6. Ahn KH, Kim HI, Lee KS, Heo JS, Kim HY, Cho GJ, et al. COVID-19 and vaccination during pregnancy: a systematic analysis using Korea National Health Insurance claims data. *Obstet Gynecol Sci* 2022;65(6):487-501.  
[PUBMED](#) | [CROSSREF](#)
7. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* 2020;370:m3320.  
[PUBMED](#) | [CROSSREF](#)
8. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in infants born to mothers with COVID-19 pneumonia. *JAMA* 2020;323(18):1848-9.  
[PUBMED](#) | [CROSSREF](#)
9. Zamaniyan M, Ebadi A, Aghajanpoor S, Rahmani Z, Haghshenas M, Azizi S. Preterm delivery, maternal death, and vertical transmission in a pregnant woman with COVID-19 infection. *Prenat Diagn* 2020;40(13):1759-61.  
[PUBMED](#) | [CROSSREF](#)
10. CDC. Precautions for people with certain medical conditions. <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>. Updated 2023. Accessed March 28, 2023.
11. Kotlyar AM, Grechukhina O, Chen A, Popkhadze S, Grimshaw A, Tal O, et al. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2021;224(1):35-53.e3.  
[PUBMED](#) | [CROSSREF](#)
12. Lee J, Lee MY, Lee J, Jang E, Bae S, Jung J, et al. Clinical characteristics and vertical transmission of severe acute respiratory syndrome coronavirus 2 infection in pregnant women and their neonates in Korea. *Infect Chemother* 2023;55(3):346-54.  
[PUBMED](#) | [CROSSREF](#)
13. CDC. COVID-19 vaccines while pregnant or breastfeeding. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html>. Updated 2023. Accessed October 6, 2023.
14. COVID-19 vaccination: a guide on pregnancy and breastfeeding. <https://www.gov.uk/government/publications/covid-19-vaccination-women-of-childbearing-age-currently-pregnant-planning-a-pregnancy-or-breastfeeding/covid-19-vaccination-a-guide-on-pregnancy-and-breastfeeding#breastfeeding>. Updated 2023. Accessed March 28, 2023.
15. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. *N Engl J Med* 2021;384(24):2273-82.  
[PUBMED](#) | [CROSSREF](#)
16. Magnus MC, Gjessing HK, Eide HN, Wilcox AJ, Fell DB, Håberg SE. COVID-19 vaccination during pregnancy and first-trimester miscarriage. *N Engl J Med* 2021;385(21):2008-10.  
[PUBMED](#) | [CROSSREF](#)

17. Kharbanda EO, Haapala J, DeSilva M, Vazquez-Benitez G, Vesco KK, Naleway AL, et al. Spontaneous abortion following COVID-19 vaccination during pregnancy. *JAMA* 2021;326(16):1629-31.  
[PUBMED](#) | [CROSSREF](#)
18. Rimmer MP, Teh JJ, Mackenzie SC, Al Wattar BH. The risk of miscarriage following COVID-19 vaccination: a systematic review and meta-analysis. *Hum Reprod* 2023;38(5):840-52.  
[PUBMED](#) | [CROSSREF](#)
19. Lipkind HS, Vazquez-Benitez G, DeSilva M, Vesco KK, Ackerman-Banks C, Zhu J, et al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth - eight integrated health care organizations, United States, December 15, 2020–July 22, 2021. *MMWR Morb Mortal Wkly Rep* 2022;71(1):26-30.  
[PUBMED](#) | [CROSSREF](#)
20. Karasek D, Baer RJ, McLemore MR, Bell AJ, Blebu BE, Casey JA, et al. The association of COVID-19 infection in pregnancy with preterm birth: a retrospective cohort study in California. *Lancet Reg Health Am* 2021;2:100027.  
[PUBMED](#) | [CROSSREF](#)
21. Muyldermans J, De Weerd L, De Brabandere L, Maertens K, Tommelein E. The effects of COVID-19 vaccination on lactating women: a systematic review of the literature. *Front Immunol* 2022;13:852928.  
[PUBMED](#) | [CROSSREF](#)
22. Hamid AAA, Rahim R, Teo SP. Pharmacovigilance and its importance for primary health care professionals. *Korean J Fam Med* 2022;43(5):290-5.  
[PUBMED](#) | [CROSSREF](#)
23. WHO-UMC. About Vigibase. <https://who-umc.org/vigibase/>. Updated 2023. Accessed March 28, 2023.
24. MedDRA. Standardised MedDRA Queries (SMQs). <https://www.meddra.org/how-to-use/tools/smq>s. Updated 2023. Accessed March 28, 2023.
25. EMA. Screening for adverse reactions in Eudravigilance. [https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance\\_en.pdf](https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf). Updated 2016. Accessed March 28, 2023.
26. EMA. Guideline on good pharmacovigilance practices (GVP): module IX addendum I - methodological aspects of signal detection from spontaneous reports of suspected adverse reactions. [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal_en.pdf). Updated 2017. Accessed October 6, 2023.
27. Sperling RS, Riley LE; Immunization and Emerging Infections Expert Work Group. Influenza vaccination, pregnancy safety, and risk of early pregnancy loss. *Obstet Gynecol* 2018;131(5):799-802.  
[PUBMED](#) | [CROSSREF](#)
28. CDC. Flu vaccine safety and pregnancy. [https://www.cdc.gov/flu/highrisk/qa\\_vacpregnant.htm](https://www.cdc.gov/flu/highrisk/qa_vacpregnant.htm). Updated 2022. Accessed March 28, 2023.
29. Murray D. Breastfeeding and the flu vaccine. <https://www.verywellfamily.com/breastfeeding-and-the-flu-vaccine-431604>. Updated 2022. Accessed March 28, 2023.
30. Brady RC, Jackson LA, Frey SE, Shane AL, Walter EB, Swamy GK, et al. Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. *Vaccine* 2018;36(31):4663-71.  
[PUBMED](#) | [CROSSREF](#)
31. Yoon H, Choi BY, Seong WJ, Cho GJ, Na S, Jung YM, et al. COVID-19 vaccine acceptance during pregnancy and influencing factors in South Korea. *J Clin Med* 2022;11(19):5733.  
[PUBMED](#) | [CROSSREF](#)
32. Blumberg D, Sridhar A, Lakshminrusimha S, Higgins RD, Saade G. COVID-19 vaccine considerations during pregnancy and lactation. *Am J Perinatol* 2021;38(6):523-8.  
[PUBMED](#) | [CROSSREF](#)
33. Prasad S, Kalafat E, Blakeway H, Townsend R, O'Brien P, Morris E, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. *Nat Commun* 2022;13(1):2414.  
[PUBMED](#) | [CROSSREF](#)
34. Magnus MC, Örtqvist AK, Dahlgvist E, Ljung R, Skår F, Oakley L, et al. Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes. *JAMA* 2022;327(15):1469-77.  
[PUBMED](#) | [CROSSREF](#)
35. Fell DB, Dhinsa T, Alton GD, Török E, Dimanlig-Cruz S, Regan AK, et al. Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. *JAMA* 2022;327(15):1478-87.  
[PUBMED](#) | [CROSSREF](#)
36. KCDC. *Causality Assessment of Adverse Events Following COVID-19 Vaccination*. Cheongju, Korea: KCDC; 2021.

37. EMA. COVID-19: latest safety data provide reassurance about use of mRNA vaccines during pregnancy. <https://www.ema.europa.eu/en/news/covid-19-latest-safety-data-provide-reassurance-about-use-mrna-vaccines-during-pregnancy>. Updated 2022. Accessed August 16, 2023.
38. England PH. JCVI issues new advice on COVID-19 vaccination for pregnant women. <https://www.gov.uk/government/news/jcvi-issues-new-advice-on-covid-19-vaccination-for-pregnant-women>. Updated 2021. Accessed September 12, 2023.
39. Australian Government. Pregnancy, breastfeeding and COVID-19 vaccines. <https://www.health.gov.au/our-work/covid-19-vaccines/who-can-get-vaccinated/pregnant-women>. Updated 2023. Accessed October 6, 2023.
40. WHO. COVID-19 advice for the public: getting vaccinated. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice>. Updated 2023. Accessed October 6, 2023.
41. Kachikis A, Englund JA, Singleton M, Covelli I, Drake AL, Eckert LO. Short-term reactions among pregnant and lactating individuals in the first wave of the COVID-19 vaccine rollout. *JAMA Netw Open* 2021;4(8):e2121310.  
[PUBMED](#) | [CROSSREF](#)
42. McLaurin-Jiang S, Garner CD, Krutsch K, Hale TW. Maternal and child symptoms following COVID-19 vaccination among breastfeeding mothers. *Breastfeed Med* 2021;16(9):702-9.  
[PUBMED](#) | [CROSSREF](#)
43. Low JM, Lee LY, Ng YP, Zhong Y, Amin Z. Breastfeeding mother and child clinical outcomes after COVID-19 vaccination. *J Hum Lact* 2022;38(1):37-42.  
[PUBMED](#) | [CROSSREF](#)
44. Eurorad. Post COVID-19 vaccination mastitis. <https://www.eurorad.org/case/17342>. Updated 2021. Accessed March 28, 2023.
45. CDC. COVID-19 vaccines while pregnant or breastfeeding. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html>. Updated 2022. Accessed March 28, 2023.
46. WHO. Questions and answers: COVID-19 vaccines and pregnancy. <https://www.who.int/publications/i/item/WHO-2019-nCoV-FAQ-Pregnancy-Vaccines-2022.1>. Updated 2022. Accessed March 28, 2023.
47. Goldshtein I, Nevo D, Steinberg DM, Rotem RS, Gorfine M, Chodick G, et al. Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women. *JAMA* 2021;326(8):728-35.  
[PUBMED](#) | [CROSSREF](#)
48. Collier AY, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. *JAMA* 2021;325(23):2370-80.  
[PUBMED](#) | [CROSSREF](#)
49. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. *Br J Clin Pharmacol* 2011;72(6):905-8.  
[PUBMED](#) | [CROSSREF](#)